The method of determining the development risk of the terminal state of the immunodeficiency for the HIV-infected patients

Jeļena Eglīte; Vladislavs Jasinskis; Gunta Stūre; Diāna Kasjko; Ludmila Vīksna; artūrs sočņevs

The method of determining the development risk of the terminal state of the immunodeficiency for the HIV-infected patients

Translated title of the contribution: Imūndeficīta terminālā stāvokļa attīstības riska noteikšanas paņēmiens ar HIV inficētiem pacientiem

Jeļena Eglīte (Inventor), Vladislavs Jasinskis (Inventor), Gunta Stūre (Inventor), Diāna Kasjko (Inventor), Ludmila Vīksna (Inventor), artūrs sočņevs (Inventor)

Rīga Stradiņš University

Research output: Intellectual property › Patent

Abstract

Invention relates to medicine, particularly to molecular genetics and infection
diseases, may be used in the discovery of human genome mutation to determine the risk of the development of the state of the immunodeficiency in HIV infected patients. The method, wherein to determine the said risk dots mutation, in particular, second exon dot mutation in codon 9, 11, 13, 28, 30, 38, 47, and 82, in the second exon of the HLA‑DRB1*01:01 gene are established, is introduced.

Translated title of the contribution	Imūndeficīta terminālā stāvokļa attīstības riska noteikšanas paņēmiens ar HIV inficētiem pacientiem
Original language	Latvian
Patent number	14901
IPC	G01N33/50
Priority date	29/04/14
Filing date	29/04/14
Publication status	Published - 20 Feb 2015

Keywords*

risk of the terminal state of the immunodeficiency
HIV-infected patients

Field of Science*

3.2 Clinical medicine

Patent expiration date

01.11.2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://databases.lrpv.gov.lv/databases/lv/patent/details/p-14-33/

Cite this

@misc{e4996d65d12344e08b4aed157cfae28f,

title = "The method of determining the development risk of the terminal state of the immunodeficiency for the HIV-infected patients",

abstract = "Invention relates to medicine, particularly to molecular genetics and infection diseases, may be used in the discovery of human genome mutation to determine the risk of the development of the state of the immunodeficiency in HIV infected patients. The method, wherein to determine the said risk dots mutation, in particular, second exon dot mutation in codon 9, 11, 13, 28, 30, 38, 47, and 82, in the second exon of the HLA‑DRB1*01:01 gene are established, is introduced.",

keywords = "risk of the terminal state of the immunodeficiency, HIV-infected patients",

author = "Jeļena Eglīte and Vladislavs Jasinskis and Gunta Stūre and Diāna Kasjko and Ludmila Vīksna and artūrs so{\v c}ņevs",

year = "2015",

month = feb,

day = "20",

language = "Latvian",

publisher = "Patent Office of the Republic of Latvia",

type = "Patent",

note = "14901; G01N33/50",

}

TY - PAT

T1 - The method of determining the development risk of the terminal state of the immunodeficiency for the HIV-infected patients

AU - Eglīte, Jeļena

AU - Jasinskis, Vladislavs

AU - Stūre, Gunta

AU - Kasjko, Diāna

AU - Vīksna, Ludmila

AU - sočņevs, artūrs

PY - 2015/2/20

Y1 - 2015/2/20

N2 - Invention relates to medicine, particularly to molecular genetics and infection diseases, may be used in the discovery of human genome mutation to determine the risk of the development of the state of the immunodeficiency in HIV infected patients. The method, wherein to determine the said risk dots mutation, in particular, second exon dot mutation in codon 9, 11, 13, 28, 30, 38, 47, and 82, in the second exon of the HLA‑DRB1*01:01 gene are established, is introduced.

AB - Invention relates to medicine, particularly to molecular genetics and infection diseases, may be used in the discovery of human genome mutation to determine the risk of the development of the state of the immunodeficiency in HIV infected patients. The method, wherein to determine the said risk dots mutation, in particular, second exon dot mutation in codon 9, 11, 13, 28, 30, 38, 47, and 82, in the second exon of the HLA‑DRB1*01:01 gene are established, is introduced.

KW - risk of the terminal state of the immunodeficiency

KW - HIV-infected patients

UR - https://www.lrpv.gov.lv/lv/media/1066/download

M3 - Patent

M1 - 14901

Y2 - 2014/04/29

PB - Patent Office of the Republic of Latvia

ER -

The method of determining the development risk of the terminal state of the immunodeficiency for the HIV-infected patients

Abstract

Keywords*

Field of Science*

Patent expiration date

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this